scholarly journals Targeting Radiotherapy to Cancer by Gene Transfer

2003 ◽  
Vol 2003 (2) ◽  
pp. 102-109 ◽  
Author(s):  
R. J. Mairs ◽  
M. Boyd
Keyword(s):  
Experimental Data ◽  
Gene Transfer ◽  
Radionuclide Therapy ◽  
Radiation Treatment ◽  
The Body ◽  
Recent Experimental Data ◽  
Low Molecular Weight ◽  
Targeted Radionuclide Therapy ◽  
Targeted Radiotherapy ◽  
Radioactive Atom

Targeted radionuclide therapy is an alternative method of radiation treatment which uses a tumor-seeking agent carrying a radioactive atom to deposits of tumor, wherever in the body they may be located. Recent experimental data signifies promise for the amalgamation of gene transfer with radionuclide targeting. This review encompasses aspects of the integration of gene manipulation and targeted radiotherapy, highlighting the possibilities of gene transfer to assist the targeting of cancer with low molecular weight radiopharmaceuticals.

scholarly journals Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response

Cancers ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 268 ◽  
Author(s):  
Javian Malcolm ◽  
Nadia Falzone ◽  
Boon Lee ◽  
Katherine Vallis
Keyword(s):  
Radionuclide Therapy ◽  
Patient Management ◽  
Radiation Treatment ◽  
External Beam Radiotherapy ◽  
Patient Treatment ◽  
Special Focus ◽  
Targeted Radionuclide Therapy ◽  
Metastatic Lesions ◽  
Prostate Cancers ◽  
Improve Patient Management

Compared to external beam radiotherapy, targeted radionuclide therapy (TRT) allows for systemic radiation treatment of metastatic lesions. Published work on recent strategies to improve patient management and response to TRT through individualising patient treatment, modifying treatment pharmacokinetics and increasing anticancer potency are discussed in this review, with a special focus on the application of clinically evaluated radiolabelled ligands and peptides in the treatment of neuroendocrine and prostate cancers.

scholarly journals Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

2021 ◽  
Author(s):  
Stephen Ahenkorah ◽  
Irwin Cassells ◽  
Christophe M Deroose ◽  
Thomas Cardinaels ◽  
Andrew R Burgoyne ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Vascular System ◽  
Chemical Properties ◽  
Proton Beam Therapy ◽  
High Energy ◽  
The Body ◽  
Magic Bullet ◽  
Targeted Radionuclide Therapy ◽  
Normal Tissues ◽  
Systemic Spread

Besides external high-energy photon or proton beam therapy, targeted radionuclide therapy (TRNT) is an alternative approach to deliver radiation to cancer cells. TRNT is distributed within the body by the vascular system and allows targeted irradiation of a primary tumor and all its metastases, resulting in substantially less collateral damage to normal tissues as compared to ex-ternal beam radiotherapy (EBRT). It is a systemic cancer therapy, tackling systemic spread of the disease, which is the cause of death in most cancer patients. The α-emitting radionuclide bis-muth-213 (213Bi) has interesting properties and can be considered as a magic bullet for TRNT. The benefits and drawbacks of targeted alpha therapy with 213Bi are discussed in this review, covering the entire chain from radionuclide production to bedside. First, the radionuclide properties and production of 225Ac and its daughter 213Bi are discussed, followed by the fundamental chemical properties of bismuth. Next, an overview of available acyclic and macrocyclic bifunctional chelators for bismuth, and general considerations for designing a 213Bi-radiopharmaceutical are provided. Finally, we will provide an overview of preclinical and clinical studies involving 213Bi-radiopharmaceuticals, as well as the future perspectives of this promising cancer treatment option.

Fusion and Breakup Reactions of 17S + 208Pb and 15C + 232ThHalo Nuclei Systems

2015 ◽  
Vol 11 (2) ◽  
pp. 2972-2978
Author(s):  
Fouad A. Majeed ◽  
Yousif A. Abdul-Hussien
Keyword(s):  
Experimental Data ◽  
Cross Section ◽  
Fusion Reaction ◽  
Fusion Cross Section ◽  
Reaction Cross ◽  
Recent Experimental Data ◽  
Barrier Distribution ◽  
Coupled Channel ◽  
Total Fusion ◽  
Full Quantum

In this study the calculations of the total fusion reaction cross section have been performed for fusion reaction systems 17F + 208Pb and 15C + 232Th which involving halo nuclei by using a semiclassical approach.The semiclassical treatment is comprising the WKB approximation to describe the relative motion between target and projectile nuclei, and Continuum Discretized Coupled Channel (CDCC) method to describe the intrinsic motion for both target and projectile nuclei. For the same of comparsion a full quantum mechanical clacualtions have been preforemd using the (CCFULL) code. Our theorticalrestuls are compared with the full quantum mechaincialcalcuations and with the recent experimental data for the total fusion reaction  checking the stability of the distancesThe coupled channel calculations of the total fusion cross section σfus, and the fusion barrier distribution Dfus. The comparsion with experiment proves that the semiclassiacl approach adopted in the present work reproduce the experimental data better that the full quantal mechanical calcautions. 

Organs dosimetry in targeted radionuclide therapy

2021 ◽  
pp. 109668
Author(s):  
Meshari Alnaaimi ◽  
Abdelmoneim Sulieman ◽  
Mohammed Alkhorayef ◽  
Hasan Salah ◽  
Musa Alduaij ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Targeted Radionuclide Therapy

scholarly journals Holistic Metabolomic Laboratory-Developed Test (LDT): Development and Use for the Diagnosis of Early-Stage Parkinson’s Disease

Metabolites ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 14
Author(s):  
Petr G. Lokhov ◽  
Dmitry L. Maslov ◽  
Steven Lichtenberg ◽  
Oxana P. Trifonova ◽  
Elena E. Balashova
Keyword(s):  
Parkinson’S Disease ◽  
Molecular Weight ◽  
Parkinson's Disease ◽  
High Resolution Mass Spectrometry ◽  
Early Stage ◽  
Disease Diagnosis ◽  
The Body ◽  
Low Molecular Weight ◽  
Low Molecular Weight Compounds

A laboratory-developed test (LDT) is a type of in vitro diagnostic test that is developed and used within a single laboratory. The holistic metabolomic LDT integrating the currently available data on human metabolic pathways, changes in the concentrations of low-molecular-weight compounds in the human blood during diseases and other conditions, and their prevalent location in the body was developed. That is, the LDT uses all of the accumulated metabolic data relevant for disease diagnosis and high-resolution mass spectrometry with data processing by in-house software. In this study, the LDT was applied to diagnose early-stage Parkinson’s disease (PD), which currently lacks available laboratory tests. The use of the LDT for blood plasma samples confirmed its ability for such diagnostics with 73% accuracy. The diagnosis was based on relevant data, such as the detection of overrepresented metabolite sets associated with PD and other neurodegenerative diseases. Additionally, the ability of the LDT to detect normal composition of low-molecular-weight compounds in blood was demonstrated, thus providing a definition of healthy at the molecular level. This LDT approach as a screening tool can be used for the further widespread testing for other diseases, since ‘omics’ tests, to which the metabolomic LDT belongs, cover a variety of them.

scholarly journals Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

2021 ◽  
Vol 14 (7) ◽  
pp. 626
Author(s):  
Julie Bolcaen ◽  
Shankari Nair ◽  
Cathryn H. S. Driver ◽  
Tebatso M. G. Boshomane ◽  
Thomas Ebenhan ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Receptor Tyrosine Kinase ◽  
Tyrosine Kinases ◽  
Radionuclide Therapy ◽  
Kinase Inhibitors ◽  
Nuclear Imaging ◽  
Therapy Resistance ◽  
Targeted Radionuclide Therapy ◽  
Therapy Strategy ◽  
Dismal Prognosis

Glioblastoma (GB) remains the most fatal brain tumor characterized by a high infiltration rate and treatment resistance. Overexpression and/or mutation of receptor tyrosine kinases is common in GB, which subsequently leads to the activation of many downstream pathways that have a critical impact on tumor progression and therapy resistance. Therefore, receptor tyrosine kinase inhibitors (RTKIs) have been investigated to improve the dismal prognosis of GB in an effort to evolve into a personalized targeted therapy strategy with a better treatment outcome. Numerous RTKIs have been approved in the clinic and several radiopharmaceuticals are part of (pre)clinical trials as a non-invasive method to identify patients who could benefit from RTKI. The latter opens up the scope for theranostic applications. In this review, the present status of RTKIs for the treatment, nuclear imaging and targeted radionuclide therapy of GB is presented. The focus will be on seven tyrosine kinase receptors, based on their central role in GB: EGFR, VEGFR, MET, PDGFR, FGFR, Eph receptor and IGF1R. Finally, by way of analyzing structural and physiological characteristics of the TKIs with promising clinical trial results, four small molecule RTKIs were selected based on their potential to become new therapeutic GB radiopharmaceuticals.

scholarly journals Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Pharmaceutics ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 599
Author(s):  
Stephen Ahenkorah ◽  
Irwin Cassells ◽  
Christophe M. Deroose ◽  
Thomas Cardinaels ◽  
Andrew R. Burgoyne ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Radionuclide Therapy ◽  
Chemical Properties ◽  
High Energy ◽  
Magic Bullet ◽  
Targeted Radionuclide Therapy ◽  
Energy Photon ◽  
Normal Tissues ◽  
Preclinical And Clinical Studies ◽  
Alpha Therapy

In contrast to external high energy photon or proton therapy, targeted radionuclide therapy (TRNT) is a systemic cancer treatment allowing targeted irradiation of a primary tumor and all its metastases, resulting in less collateral damage to normal tissues. The α-emitting radionuclide bismuth-213 (213Bi) has interesting properties and can be considered as a magic bullet for TRNT. The benefits and drawbacks of targeted alpha therapy with 213Bi are discussed in this review, covering the entire chain from radionuclide production to bedside. First, the radionuclide properties and production of 225Ac and its daughter 213Bi are discussed, followed by the fundamental chemical properties of bismuth. Next, an overview of available acyclic and macrocyclic bifunctional chelators for bismuth and general considerations for designing a 213Bi-radiopharmaceutical are provided. Finally, we provide an overview of preclinical and clinical studies involving 213Bi-radiopharmaceuticals, as well as the future perspectives of this promising cancer treatment option.

Sign in / Sign up

Export Citation Format

Share Document